VTRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VTRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Viatris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $2,456 Mil. Viatris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $14,923 Mil. Viatris's annualized EBITDA for the quarter that ended in Jun. 2024 was $2,161 Mil. Viatris's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 8.04.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Viatris's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of Viatris was 13.13. The lowest was 3.04. And the median was 4.75.
The historical data trend for Viatris's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | 4.80 | 13.13 | 5.22 | 3.04 | 5.22 |
Viatris Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | 4.05 | 3.81 | -65.89 | 4.40 | 8.04 |
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Viatris's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viatris's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Viatris's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (2017.7 | + | 16353.5) | / | 3516.5 | |
= | 5.22 |
Viatris's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (2456.1 | + | 14923.1) | / | 2161.2 | |
= | 8.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.
Viatris (NAS:VTRS) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Viatris's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Rajiv Malik | director, officer: President | BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
Brian Roman | officer: Global General Counsel | 1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
Anthony Mauro | officer: See Remarks | BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
Paul Campbell | officer: See Remarks | BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
Dillon Joellen Lyons | director | BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL |
Xiangyang (sean) Ni | officer: President, Greater China | 1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
Andrew Cuneo | officer: See Remarks | 1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
Leo Frans Groothuis | director | 1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
Scott Andrew Smith | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Elisha W Finney | director | C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304 |
Van Der Meer Mohr Pauline | director | 1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
Menassie Taddese | officer: See Remarks | 1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
Robert J Coury | director, officer: Executive Chairman | BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
W Don Cornwell | director | |
James M Kilts | director | 120 PARK AVE, NEW YORK NY 10017 |
From GuruFocus
By PRNewswire • 07-02-2024
By PRNewswire • 09-18-2024
By PRNewswire • 08-06-2024
By ACCESSWIRE • 07-23-2024
By PRNewswire • 08-23-2024
By PRNewswire • 06-25-2024
By GuruFocus Research • 08-09-2024
By ACCESSWIRE • 09-16-2024
By GuruFocus Research • 09-12-2024
By GuruFocus Research • 09-20-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.